Islamic State & Moderna

Islamic State: Militants linked to the Islamic State group have carried out attacks in Democratic Republic of the Congo — Ituri Province, further complicating Ebola response efforts and displacing large populations.

Moderna: Moderna is utilizing its mRNA technology to develop a vaccine for the Bundibugyo strain of Ebola, with funding from CEPI, aiming to rapidly train the body to fight the virus.

Islamic State: Islamic State-backed militants contribute to the violence and insecurity in Democratic Republic of the Congo — Ituri Province, further complicating the Ebola response by disrupting health facilities and displacing populations.

Moderna: Moderna is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Islamic State: Affiliated with ADF, adding to the complex security environment.

Moderna: Authorized to begin Phase 1 trials for a Bundibugyo vaccine, using mRNA technology. Potential for significant revenue if successful.

Islamic State: Militants affiliated with ISIL reportedly attacked a village in Ituri, causing displacement. Such attacks exacerbate the humanitarian crisis.

Moderna: Developed an mRNA-based Bundibugyo vaccine candidate, with Phase 1 trials starting in Canada. Its mRNA platform could offer a rapid response to emerging outbreaks.

Islamic State: Militants linked to the Islamic State have conducted attacks in Ituri, exacerbating the security crisis and impeding humanitarian aid for the Ebola response.

Moderna: Moderna is one of the entities developing an experimental vaccine for the Bundibugyo virus, which could lead to future revenue and enhance its reputation in vaccine development.